NCT02782845 - An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions

Non-Hodgkin's Lymphoma

Interventions

DRUG

Chemotherapy

The choice of CT will be as per standard of care and protocol does not specify any particular CT drug.

DRUG

Immunochemotherapy

The choice of ICT will be as per standard of care and protocol does not specify any particular ICT drug.

DRUG

Pegfilgrastim

Pegfilgrastim will be administered at a fixed dose of 6 mg subcutaneously 24 hours after the last dose of CT or ICT is received for 6 cycles.

Trial Locations (19)

10700

Mexico City

11520

Mexico City

31000

Mexico City

31100

Chihuahua City

31240

Chihuahua City

37320

León

37520

León

44139

Guadalajara

52140

Toluca

52763

Estado de México

63120

Tepic

72530

Puebla City

76000

Querétaro

85000

Obregón

91980

Veracruz

Unknown

Bogotá

01120

Mexico City

03100

Mexico City

06770

Mexico City

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY